Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma shot could match leading biologics in preventing severe attacks

NCT ID NCT04718389

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether switching to a new drug called depemokimab (GSK3511294) works as well as staying on current treatments (mepolizumab or benralizumab) for people with severe asthma linked to high eosinophils. Over 1,700 adults and teens took part for 52 weeks, continuing their usual asthma medicines. The main goal was to compare how often severe asthma attacks happened, requiring steroids or hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,717 people

The number who actually took part.

Started

Jan 2021

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria for study: * Adult and adolescent participants more than or equal to (\>=)12 years of age, at the time of signing the informed consent/assent. * Participants who have a documented physician diagnosis of asthma for \>=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines. * Participants receiving either mepolizumab 100 milligrams (mg) or benralizumab 30 mg for \>=12 months prior to screening and have a documented benefit to therapy assessed by either: (i) \>=50% reduction in exacerbation frequency since initiating treatment, or (ii) \>=50% reduction in maintenance OCS use since initiating treatment, or (iii) No exacerbations in the past 6 months whilst receiving anti-IL-5/5R therapy and an Asthma Control Questionnaire (ACQ)-5 score of less than or equal to (\<=)1.5 at screening. * A well-documented requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS. The maintenance ICS dose must be \>=440 micrograms (mcg) fluticasone propionate (FP) hydrofluoroalkane (HFA) product daily, or clinically comparable. Participants who are treated with medium dose ICS will also need to be treated with a LABA to qualify for inclusion. * Current treatment with at least one additional controller medication, besides ICS \[for example (e.g.), LABA, LAMA, leukotriene receptor antagonist (LTRA), or theophylline\]. Key exclusion criteria for study: * Participants with presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer. * Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis * A current malignancy or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded). * Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. * Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis excluded prior to enrolment. * Participants who have received Omalizumab (Xolair), dupilumab (Dupixent) or reslizumab (Cinqair/Cinqaero) within 130 days prior to Visit 1. * Participants who have received any Monoclonal antibody (mAb) within 5 half-lives of Visit 1. * Corrected QT interval using Fridericia's formula (QTcF) \>=450 milliseconds (msec) or QTcF \>=480 msec for participants with Bundle Branch Block at screening Visit 1. * Current smokers or former smokers with a smoking history of \>=10 pack years (number of pack years equal to \[number of cigarettes per day/20\] times number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1. * Participants with allergy/intolerance to a mAb or biologic. Key exclusion criteria for randomization: * Evidence of a clinically significant abnormality in the 12-lead electrocardiogram (ECG) over-read conducted at Screening Visit 1, based on the evaluation of the investigator, or QTcF \>=450 msec or QTcF \>=480 msec for participants with Bundle Branch Block, at randomization Visit 2. * Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable. If the 8-week screening period has elapsed, then the participant should be considered a run-in failure. * Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • GSK Investigational Site

    Birmingham, Alabama, 35209, United States

  • GSK Investigational Site

    Scottsboro, Alabama, 35768, United States

  • GSK Investigational Site

    Litchfield Park, Arizona, 85340, United States

  • GSK Investigational Site

    Phoenix, Arizona, 85054, United States

  • GSK Investigational Site

    Scottsdale, Arizona, 85251, United States

  • GSK Investigational Site

    Bakersfield, California, 93301, United States

  • GSK Investigational Site

    Encinitas, California, 92024, United States

  • GSK Investigational Site

    Huntington Beach, California, 92647, United States

  • GSK Investigational Site

    Los Angeles, California, 90048, United States

  • GSK Investigational Site

    Newport Beach, California, 92663, United States

  • GSK Investigational Site

    Oxnard, California, 93036, United States

  • GSK Investigational Site

    Rancho Cucamonga, California, 91730, United States

  • GSK Investigational Site

    Redondo Beach, California, 90277, United States

  • GSK Investigational Site

    Redwood City, California, 94063, United States

  • GSK Investigational Site

    Riverside, California, 91786, United States

  • GSK Investigational Site

    San Diego, California, 92123, United States

  • GSK Investigational Site

    San Diego, California, 92307, United States

  • GSK Investigational Site

    Valencia, California, 91324, United States

  • GSK Investigational Site

    Woodland, California, 95695, United States

  • GSK Investigational Site

    Aurora, Colorado, 80238, United States

  • GSK Investigational Site

    Colorado Springs, Colorado, 80907, United States

  • GSK Investigational Site

    Colorado Springs, Colorado, 80923, United States

  • GSK Investigational Site

    Denver, Colorado, 80209, United States

  • GSK Investigational Site

    Wheat Ridge, Colorado, 80033, United States

  • GSK Investigational Site

    New Haven, Connecticut, 06511, United States

  • GSK Investigational Site

    Aventura, Florida, 33180, United States

  • GSK Investigational Site

    Clearwater, Florida, 33765-2103, United States

  • GSK Investigational Site

    Fort Lauderdale, Florida, 33316, United States

  • GSK Investigational Site

    Gainesville, Florida, 32610, United States

  • GSK Investigational Site

    Hialeah, Florida, 33014, United States

  • GSK Investigational Site

    Hialeah, Florida, 33016, United States

  • GSK Investigational Site

    Jacksonville, Florida, 32209, United States

  • GSK Investigational Site

    Kissimmee, Florida, 34746, United States

  • GSK Investigational Site

    Loxahatchee Groves, Florida, 33470, United States

  • GSK Investigational Site

    Miami, Florida, 33125, United States

  • GSK Investigational Site

    Miami, Florida, 33126, United States

  • GSK Investigational Site

    Miami, Florida, 33144, United States

  • GSK Investigational Site

    Miami, Florida, 33166, United States

  • GSK Investigational Site

    Miami, Florida, 33172, United States

  • GSK Investigational Site

    Miami, Florida, 33186, United States

  • GSK Investigational Site

    Miami Lakes, Florida, 33014, United States

  • GSK Investigational Site

    Miami Lakes, Florida, 33125, United States

  • GSK Investigational Site

    North Palm Beach, Florida, 33408, United States

  • GSK Investigational Site

    Orlando, Florida, 32803, United States

  • GSK Investigational Site

    Orlando, Florida, 32806, United States

  • GSK Investigational Site

    Orlando, Florida, 32819, United States

  • GSK Investigational Site

    Sebring, Florida, 33870, United States

  • GSK Investigational Site

    Tallahassee, Florida, 32308, United States

  • GSK Investigational Site

    Calhoun, Georgia, 30701, United States

  • GSK Investigational Site

    Glenview, Illinois, 60077, United States

  • GSK Investigational Site

    Evansville, Indiana, 47715, United States

  • GSK Investigational Site

    Overland Park, Kansas, 66210, United States

  • GSK Investigational Site

    Lexington, Kentucky, 40509, United States

  • GSK Investigational Site

    Owensboro, Kentucky, 42301, United States

  • GSK Investigational Site

    Bangor, Maine, 04401, United States

  • GSK Investigational Site

    Baltimore, Maryland, 21162, United States

  • GSK Investigational Site

    Baltimore, Maryland, 21224, United States

  • GSK Investigational Site

    Chevy Chase, Maryland, 20815, United States

  • GSK Investigational Site

    Boston, Massachusetts, 02115, United States

  • GSK Investigational Site

    Burlington, Massachusetts, 01805, United States

  • GSK Investigational Site

    New Bedford, Massachusetts, 02740, United States

  • GSK Investigational Site

    North Dartmouth, Massachusetts, 02747, United States

  • GSK Investigational Site

    Ann Arbor, Michigan, 48109, United States

  • GSK Investigational Site

    Flint, Michigan, 48507, United States

  • GSK Investigational Site

    Warren, Michigan, 48088, United States

  • GSK Investigational Site

    Minneapolis, Minnesota, 55454, United States

  • GSK Investigational Site

    Gulfport, Mississippi, 36608, United States

  • GSK Investigational Site

    Jackson, Mississippi, 39216, United States

  • GSK Investigational Site

    Chesterfield, Missouri, 63017, United States

  • GSK Investigational Site

    Saint Charles, Missouri, 63301, United States

  • GSK Investigational Site

    St Louis, Missouri, 63110, United States

  • GSK Investigational Site

    Lincoln, Nebraska, 68505, United States

  • GSK Investigational Site

    Omaha, Nebraska, 68198-5990, United States

  • GSK Investigational Site

    Brick, New Jersey, 08724, United States

  • GSK Investigational Site

    Northfield, New Jersey, 08225, United States

  • GSK Investigational Site

    Riverdale, New Jersey, 07457, United States

  • GSK Investigational Site

    Toms River, New Jersey, 08755, United States

  • GSK Investigational Site

    Brooklyn, New York, 11215, United States

  • GSK Investigational Site

    Corning, New York, 14845, United States

  • GSK Investigational Site

    Great Neck, New York, 11040, United States

  • GSK Investigational Site

    New York, New York, 60301, United States

  • GSK Investigational Site

    The Bronx, New York, 10459-2417, United States

  • GSK Investigational Site

    The Bronx, New York, 10467, United States

  • GSK Investigational Site

    Asheville, North Carolina, 28803, United States

  • GSK Investigational Site

    Huntersville, North Carolina, 28078, United States

  • GSK Investigational Site

    Wilmington, North Carolina, 28401, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27157, United States

  • GSK Investigational Site

    Cincinnati, Ohio, 45229, United States

  • GSK Investigational Site

    Cincinnati, Ohio, 45231, United States

  • GSK Investigational Site

    Corvallis, Oregon, 97330, United States

  • GSK Investigational Site

    Altoona, Pennsylvania, 15801, United States

  • GSK Investigational Site

    Altoona, Pennsylvania, 16601, United States

  • GSK Investigational Site

    Hershey, Pennsylvania, 17033, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19140, United States

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15241, United States

  • GSK Investigational Site

    Wyomissing, Pennsylvania, 19610, United States

  • GSK Investigational Site

    Warwick, Rhode Island, 02886, United States

  • GSK Investigational Site

    Rock Hill, South Carolina, 29732, United States

  • GSK Investigational Site

    Spartanburg, South Carolina, 29303, United States

  • GSK Investigational Site

    Hendersonville, Tennessee, 37075, United States

  • GSK Investigational Site

    Knoxville, Tennessee, 37909, United States

  • GSK Investigational Site

    Amarillo, Texas, 79106, United States

  • GSK Investigational Site

    Amarillo, Texas, 79124, United States

  • GSK Investigational Site

    Dallas, Texas, 75225, United States

  • GSK Investigational Site

    Dallas, Texas, 75235, United States

  • GSK Investigational Site

    Dallas, Texas, 75246, United States

  • GSK Investigational Site

    Houston, Texas, 77030, United States

  • GSK Investigational Site

    Houston, Texas, 77429, United States

  • GSK Investigational Site

    Kerrville, Texas, 78028, United States

  • GSK Investigational Site

    San Antonio, Texas, 78207, United States

  • GSK Investigational Site

    San Antonio, Texas, 78229, United States

  • GSK Investigational Site

    San Antonio, Texas, 78258, United States

  • GSK Investigational Site

    Murray, Utah, 84107, United States

  • GSK Investigational Site

    Richmond, Virginia, 23298, United States

  • GSK Investigational Site

    Williamsburg, Virginia, 23188, United States

  • GSK Investigational Site

    Bellingham, Washington, 98225, United States

  • GSK Investigational Site

    Seattle, Washington, 98115, United States

  • GSK Investigational Site

    Greenfield, Wisconsin, 53228, United States

  • GSK Investigational Site

    Macquarie University, New South Wales, 2109, Australia

  • GSK Investigational Site

    Sydney, New South Wales, 2010, Australia

  • GSK Investigational Site

    Westmead, New South Wales, 2145, Australia

  • GSK Investigational Site

    Cairns, Queensland, 4870, Australia

  • GSK Investigational Site

    South Brisbane, Queensland, 4101, Australia

  • GSK Investigational Site

    Adelaide, South Australia, 5000, Australia

  • GSK Investigational Site

    Bedford Park, South Australia, 5042, Australia

  • GSK Investigational Site

    North Adelaide, South Australia, 5006, Australia

  • GSK Investigational Site

    Toorak Gardens, South Australia, 5065, Australia

  • GSK Investigational Site

    Woodville, South Australia, 5011, Australia

  • GSK Investigational Site

    Box Hill, Victoria, 3128, Australia

  • GSK Investigational Site

    Clayton, Victoria, 3168, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, 3065, Australia

  • GSK Investigational Site

    Frankston, Victoria, 3199, Australia

  • GSK Investigational Site

    Melbourne, Victoria, 3181, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, 6009, Australia

  • GSK Investigational Site

    Feldbach, 8330, Austria

  • GSK Investigational Site

    Vienna, 1130, Austria

  • GSK Investigational Site

    Calgary, Alberta, T2N 4Z6, Canada

  • GSK Investigational Site

    Edmonton, Alberta, T5J 3S9, Canada

  • GSK Investigational Site

    Moncton, New Brunswick, E1C 5K4, Canada

  • GSK Investigational Site

    Ajax, Ontario, L1S 2J5, Canada

  • GSK Investigational Site

    Ottawa, Ontario, K1H 1E4, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5G 1E2, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5T 3A9, Canada

  • GSK Investigational Site

    Windsor, Ontario, N8X 1T3, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, J4V 2H1, Canada

  • GSK Investigational Site

    Québec, Quebec, G1V 4G5, Canada

  • GSK Investigational Site

    Québec, Quebec, G1V 4W2, Canada

  • GSK Investigational Site

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • GSK Investigational Site

    Tampere, 33520, Finland

  • GSK Investigational Site

    Turku, 20521, Finland

  • GSK Investigational Site

    Amiens, 80000, France

  • GSK Investigational Site

    Annecy, 74011, France

  • GSK Investigational Site

    Antony, 92160, France

  • GSK Investigational Site

    Besançon, 25030, France

  • GSK Investigational Site

    Brest, 29609, France

  • GSK Investigational Site

    Caen, 14033, France

  • GSK Investigational Site

    Cannes, 06414, France

  • GSK Investigational Site

    Cholet, 49300, France

  • GSK Investigational Site

    Dijon, 21079, France

  • GSK Investigational Site

    La Tronche, 38700, France

  • GSK Investigational Site

    Le Mans, 72037, France

  • GSK Investigational Site

    Lille, 59037, France

  • GSK Investigational Site

    Lyon, 69317, France

  • GSK Investigational Site

    Marseille, 13003., France

  • GSK Investigational Site

    Marseille, 13015, France

  • GSK Investigational Site

    Montfermeil, 93370, France

  • GSK Investigational Site

    Montivilliers, 76290, France

  • GSK Investigational Site

    Montpellier, 34295, France

  • GSK Investigational Site

    Nice, 06001, France

  • GSK Investigational Site

    Paris, 75014, France

  • GSK Investigational Site

    Paris, 75015, France

  • GSK Investigational Site

    Paris, 75877, France

  • GSK Investigational Site

    Pontoise, 95303, France

  • GSK Investigational Site

    Rouen, 76031, France

  • GSK Investigational Site

    Saint-Herblain, 44093, France

  • GSK Investigational Site

    Strasbourg, 67091, France

  • GSK Investigational Site

    Suresnes, 92150, France

  • GSK Investigational Site

    Toulouse, 31059, France

  • GSK Investigational Site

    Tours, 37044, France

  • GSK Investigational Site

    Aschaffenburg, 63739, Germany

  • GSK Investigational Site

    Bendorf, 56170, Germany

  • GSK Investigational Site

    Berlin, 10969, Germany

  • GSK Investigational Site

    Berlin, 12159, Germany

  • GSK Investigational Site

    Berlin, 12203, Germany

  • GSK Investigational Site

    Bonn, 53119, Germany

  • GSK Investigational Site

    Bonn, 53127, Germany

  • GSK Investigational Site

    Darmstadt, 64283, Germany

  • GSK Investigational Site

    Frankfurt, 60389, Germany

  • GSK Investigational Site

    Frankfurt, 60596, Germany

  • GSK Investigational Site

    Fürstenwalde, 15517, Germany

  • GSK Investigational Site

    Geesthacht, 21502, Germany

  • GSK Investigational Site

    Halle, 06108, Germany

  • GSK Investigational Site

    Halle, 06120, Germany

  • GSK Investigational Site

    Hamburg, 20354, Germany

  • GSK Investigational Site

    Hanover, 30625, Germany

  • GSK Investigational Site

    Landsberg, 86899, Germany

  • GSK Investigational Site

    Leipzig, 04207, Germany

  • GSK Investigational Site

    Leipzig, 04275, Germany

  • GSK Investigational Site

    Leipzig, 04347, Germany

  • GSK Investigational Site

    Lübeck, 23552, Germany

  • GSK Investigational Site

    Lübeck, 23558, Germany

  • GSK Investigational Site

    Magdeburg, 39120, Germany

  • GSK Investigational Site

    Mainz, 55128, Germany

  • GSK Investigational Site

    München, 81241, Germany

  • GSK Investigational Site

    Neu-Isenburg, 63263, Germany

  • GSK Investigational Site

    Rheine, 48431, Germany

  • GSK Investigational Site

    Schleswig, 24837, Germany

  • GSK Investigational Site

    Cork, T12 DFK4, Ireland

  • GSK Investigational Site

    Dublin, D04 T6F4, Ireland

  • GSK Investigational Site

    Dublin, D08 NHY1, Ireland

  • GSK Investigational Site

    Beersheba, 8410101, Israel

  • GSK Investigational Site

    Haifa, 34362, Israel

  • GSK Investigational Site

    Jerusalem, 91031, Israel

  • GSK Investigational Site

    Jerusalem, 91120, Israel

  • GSK Investigational Site

    Kfar Saba, 44281, Israel

  • GSK Investigational Site

    Petah Tikva, 49100, Israel

  • GSK Investigational Site

    Ramat Gan, 52621, Israel

  • GSK Investigational Site

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    Zrifin, 70300, Israel

  • GSK Investigational Site

    Bari, 70124, Italy

  • GSK Investigational Site

    Bergamo, 24127, Italy

  • GSK Investigational Site

    Bologna, 40138, Italy

  • GSK Investigational Site

    Brescia, 25123, Italy

  • GSK Investigational Site

    Catania, 95123, Italy

  • GSK Investigational Site

    Ferrara, 44124, Italy

  • GSK Investigational Site

    Florence, 50134, Italy

  • GSK Investigational Site

    Genova, 16132, Italy

  • GSK Investigational Site

    Mantua, 46100, Italy

  • GSK Investigational Site

    Milan, 20122, Italy

  • GSK Investigational Site

    Milan, 20123, Italy

  • GSK Investigational Site

    Milan, 20132, Italy

  • GSK Investigational Site

    Milan, 20162, Italy

  • GSK Investigational Site

    Modena, 41124, Italy

  • GSK Investigational Site

    Monserrato CA, 09042, Italy

  • GSK Investigational Site

    Naples, 80131, Italy

  • GSK Investigational Site

    Padova, 35128, Italy

  • GSK Investigational Site

    Palermo, 90127, Italy

  • GSK Investigational Site

    Pavia, 27100, Italy

  • GSK Investigational Site

    Perugia, 06156, Italy

  • GSK Investigational Site

    Pisa, 56100, Italy

  • GSK Investigational Site

    Reggio Emilia, 42100, Italy

  • GSK Investigational Site

    Roma, 168, Italy

  • GSK Investigational Site

    Salerno, 84131, Italy

  • GSK Investigational Site

    Sassari, 7100, Italy

  • GSK Investigational Site

    Siena, 53100, Italy

  • GSK Investigational Site

    Torino, 10128, Italy

  • GSK Investigational Site

    Torrette AN, 60020, Italy

  • GSK Investigational Site

    Treviso, 31100, Italy

  • GSK Investigational Site

    Trieste, 34139, Italy

  • GSK Investigational Site

    Verona, 37134, Italy

  • GSK Investigational Site

    Shibuya-Ku, Tokyo, 150-8935, Japan

  • GSK Investigational Site

    Aichi, 454-8509, Japan

  • GSK Investigational Site

    Aichi, 470-1192, Japan

  • GSK Investigational Site

    Aichi, 489-8642, Japan

  • GSK Investigational Site

    Akita, 010-8543, Japan

  • GSK Investigational Site

    Ehime, 790-0024, Japan

  • GSK Investigational Site

    Fukuoka, 802-0052, Japan

  • GSK Investigational Site

    Fukuoka, 805-8508, Japan

  • GSK Investigational Site

    Fukuoka, 806-8501, Japan

  • GSK Investigational Site

    Fukuoka, 811-1394, Japan

  • GSK Investigational Site

    Fukuoka, 813-0017, Japan

  • GSK Investigational Site

    Fukuoka, 830-0011, Japan

  • GSK Investigational Site

    Fukushima, 960-1295, Japan

  • GSK Investigational Site

    Gifu, 509-6134, Japan

  • GSK Investigational Site

    Hiroshima, 734-8530, Japan

  • GSK Investigational Site

    Hiroshima, 735-8585, Japan

  • GSK Investigational Site

    Hiroshima, 737-0023, Japan

  • GSK Investigational Site

    Hokkaido, 064-0804, Japan

  • GSK Investigational Site

    Hyōgo, 650-0047, Japan

  • GSK Investigational Site

    Hyōgo, 653-0013, Japan

  • GSK Investigational Site

    Ibaraki, 302-0022, Japan

  • GSK Investigational Site

    Ibaraki, 319-1113, Japan

  • GSK Investigational Site

    Ishikawa, 920-0293, Japan

  • GSK Investigational Site

    Kagawa, 762-8550, Japan

  • GSK Investigational Site

    Kagoshima, 890-8520, Japan

  • GSK Investigational Site

    Kanagawa, 231-8682, Japan

  • GSK Investigational Site

    Kanagawa, 232-0024, Japan

  • GSK Investigational Site

    Kanagawa, 236-0004, Japan

  • GSK Investigational Site

    Kanagawa, 236-0051, Japan

  • GSK Investigational Site

    Kanagawa, 254-8502, Japan

  • GSK Investigational Site

    Mie, 510-8561, Japan

  • GSK Investigational Site

    Mie, 511-0061, Japan

  • GSK Investigational Site

    Mie, 515-8544, Japan

  • GSK Investigational Site

    Miyagi, 981-8563, Japan

  • GSK Investigational Site

    Nagano, 386-8610, Japan

  • GSK Investigational Site

    Niigata, 951-8520, Japan

  • GSK Investigational Site

    Numakunai, 020-8505, Japan

  • GSK Investigational Site

    Okayama, 701-0304, Japan

  • GSK Investigational Site

    Okayama, 702-8055, Japan

  • GSK Investigational Site

    Osaka, 530-0012, Japan

  • GSK Investigational Site

    Osaka, 543-8555, Japan

  • GSK Investigational Site

    Osaka, 560-8552, Japan

  • GSK Investigational Site

    Osaka, 569-1096, Japan

  • GSK Investigational Site

    Osaka, 569-1192, Japan

  • GSK Investigational Site

    Osaka, 569-8686, Japan

  • GSK Investigational Site

    Osaka, 572-8551, Japan

  • GSK Investigational Site

    Osaka, 593-8304, Japan

  • GSK Investigational Site

    Osaka, 596-8501, Japan

  • GSK Investigational Site

    Shimane, 693-8501, Japan

  • GSK Investigational Site

    Shizuoka, 420-8527, Japan

  • GSK Investigational Site

    Shizuoka, 430-8525, Japan

  • GSK Investigational Site

    Tokyo, 103-0027, Japan

  • GSK Investigational Site

    Tokyo, 105-8471, Japan

  • GSK Investigational Site

    Tokyo, 113-8431, Japan

  • GSK Investigational Site

    Tokyo, 113-8519, Japan

  • GSK Investigational Site

    Tokyo, 136-0075, Japan

  • GSK Investigational Site

    Tokyo, 141-8625, Japan

  • GSK Investigational Site

    Tokyo, 142-8666, Japan

  • GSK Investigational Site

    Tokyo, 160-8582, Japan

  • GSK Investigational Site

    Tokyo, 162-8655, Japan

  • GSK Investigational Site

    Tokyo, 173-8606, Japan

  • GSK Investigational Site

    Tokyo, 187-8510, Japan

  • GSK Investigational Site

    Tokyo, 190-0014, Japan

  • GSK Investigational Site

    Tokyo, 204-8585, Japan

  • GSK Investigational Site

    Toyama, 930-8550, Japan

  • GSK Investigational Site

    Wakayama, 640-8558, Japan

  • GSK Investigational Site

    Arnhem, 6815 AD, Netherlands

  • GSK Investigational Site

    Breda, 4818 CK, Netherlands

  • GSK Investigational Site

    Deventer, 7416 SE, Netherlands

  • GSK Investigational Site

    Eindhoven, 5623 EJ, Netherlands

  • GSK Investigational Site

    Enschede, 7513 ER, Netherlands

  • GSK Investigational Site

    Harderwijk, 3844 DG, Netherlands

  • GSK Investigational Site

    Leeuwarden, 8934 AD, Netherlands

  • GSK Investigational Site

    Nijmegen, 6532 SZ, Netherlands

  • GSK Investigational Site

    Rotterdam, 3045 PM, Netherlands

  • GSK Investigational Site

    Zwolle, 8025 AB, Netherlands

  • GSK Investigational Site

    Bergen, 5021, Norway

  • GSK Investigational Site

    Lrenskog, 1478, Norway

  • GSK Investigational Site

    Coimbra, 3041-801, Portugal

  • GSK Investigational Site

    Guarda, 6300-035, Portugal

  • GSK Investigational Site

    Lisbon, 1649-035, Portugal

  • GSK Investigational Site

    Matosinhos Municipality, 4464-509, Portugal

  • GSK Investigational Site

    Guaynabo, 00968, Puerto Rico

  • GSK Investigational Site

    Golnik, 4204, Slovenia

  • GSK Investigational Site

    Alcorcón, 28922, Spain

  • GSK Investigational Site

    Almería, 04009, Spain

  • GSK Investigational Site

    Badalona, 08916, Spain

  • GSK Investigational Site

    Barcelona, 08003, Spain

  • GSK Investigational Site

    Barcelona, 08017, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08036, Spain

  • GSK Investigational Site

    Barcelona, 08950, Spain

  • GSK Investigational Site

    Barcelona, 8025, Spain

  • GSK Investigational Site

    Benalmádena, 29631, Spain

  • GSK Investigational Site

    Bilbao, 48013, Spain

  • GSK Investigational Site

    Granada, 18014, Spain

  • GSK Investigational Site

    Jerez de la Frontera, 11407, Spain

  • GSK Investigational Site

    La Laguna Santa Cruz, 38320, Spain

  • GSK Investigational Site

    Madrid, 28031, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Málaga, 29010, Spain

  • GSK Investigational Site

    MErida Badajoz, 06800, Spain

  • GSK Investigational Site

    Pamplona, 31008, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, 28223, Spain

  • GSK Investigational Site

    Salamanca, 37007, Spain

  • GSK Investigational Site

    Santander, 39008, Spain

  • GSK Investigational Site

    Santiago de Compostela, 15706, Spain

  • GSK Investigational Site

    Valencia, 46015, Spain

  • GSK Investigational Site

    Valencia, 46017, Spain

  • GSK Investigational Site

    Via-Real CastellOn, 12540, Spain

  • GSK Investigational Site

    Vitoria-Gasteiz, 01009, Spain

  • GSK Investigational Site

    Zaragoza, 50009, Spain

  • GSK Investigational Site

    Linköping, SE-58758, Sweden

  • GSK Investigational Site

    Lund, SE-221 85, Sweden

  • GSK Investigational Site

    Östersund, SE-831 83, Sweden

  • GSK Investigational Site

    Stockholm, SE-141 86, Sweden

  • GSK Investigational Site

    Uppsala, SE-751 85, Sweden

  • GSK Investigational Site

    Aarau, 5001, Switzerland

  • GSK Investigational Site

    Basel, 4031, Switzerland

  • GSK Investigational Site

    Liestal, 4410, Switzerland

  • GSK Investigational Site

    Sankt Gallen, 9007, Switzerland

  • GSK Investigational Site

    Banchiau Taipei, 220, Taiwan

  • GSK Investigational Site

    Changhua, 500, Taiwan

  • GSK Investigational Site

    Linkou - Taoyuan Hsien, 333, Taiwan

  • GSK Investigational Site

    Taichung, 404, Taiwan

  • GSK Investigational Site

    Taichung, 40705, Taiwan

  • GSK Investigational Site

    Taipei, 100, Taiwan

  • GSK Investigational Site

    Belfast, BT9 7AB, United Kingdom

  • GSK Investigational Site

    Birmingham, B9 5SS, United Kingdom

  • GSK Investigational Site

    Bradford, BD9 6RJ, United Kingdom

  • GSK Investigational Site

    Bristol Avon, BS10 5NB, United Kingdom

  • GSK Investigational Site

    Cottingham, HU16 5JQ, United Kingdom

  • GSK Investigational Site

    Exeter, EX2 5DW, United Kingdom

  • GSK Investigational Site

    Glasgow, G31 2ER, United Kingdom

  • GSK Investigational Site

    Glasgow, G51 4TF, United Kingdom

  • GSK Investigational Site

    Liverpool, L7 8XP, United Kingdom

  • GSK Investigational Site

    London, EC1A 7BE, United Kingdom

  • GSK Investigational Site

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • GSK Investigational Site

    Nottingham, NG5 1PB, United Kingdom

  • GSK Investigational Site

    Oxford, OX3 9DU, United Kingdom

  • GSK Investigational Site

    Portsmouth, PO6 3LY, United Kingdom

  • GSK Investigational Site

    Preston, PR2 9HT, United Kingdom

  • GSK Investigational Site

    Wakefield, WF1 4DG, United Kingdom

  • GSK Investigational Site

    Wishaw, ML6 0JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.